Cite
Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review.
MLA
Nadaraja, Sambavy, et al. “Value of 2-[18F]FDG-PET/CT in Identifying Immune-Related Adverse Events in Patients with Melanoma or Non-Small Cell Lung Cancer: A Systematic Scoping Review.” Clinical & Translational Imaging, vol. 12, no. 2, Apr. 2024, pp. 187–95. EBSCOhost, https://doi.org/10.1007/s40336-024-00618-3.
APA
Nadaraja, S., Helsing, J., Naghavi-Bezhad, M., Land, L. H., Ruhlmann, C. H., Gerke, O., & Hildebrandt, M. G. (2024). Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review. Clinical & Translational Imaging, 12(2), 187–195. https://doi.org/10.1007/s40336-024-00618-3
Chicago
Nadaraja, Sambavy, Jonas Helsing, Mohammad Naghavi-Bezhad, Lotte H. Land, Christina H. Ruhlmann, Oke Gerke, and Malene G. Hildebrandt. 2024. “Value of 2-[18F]FDG-PET/CT in Identifying Immune-Related Adverse Events in Patients with Melanoma or Non-Small Cell Lung Cancer: A Systematic Scoping Review.” Clinical & Translational Imaging 12 (2): 187–95. doi:10.1007/s40336-024-00618-3.